Inolimomab: Difference between revisions
Content deleted Content added
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number'). |
consistent citation formatting |
||
| (18 intermediate revisions by 15 users not shown) | |||
| Line 1: | Line 1: | ||
| ⚫ | |||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| verifiedrevid = |
| verifiedrevid = 458271906 |
||
| image = |
| image = |
||
<!-- Monoclonal antibody data --> |
|||
| ⚫ | |||
| type = mab |
| type = mab |
||
| mab_type = mab |
| mab_type = mab |
||
| source = o |
| source = o |
||
| target = [[CD25]] |
| target = [[CD25]] |
||
| ⚫ | |||
| ⚫ | |||
| tradename = |
| tradename = |
||
| pregnancy_AU = |
| pregnancy_AU = |
||
| Line 21: | Line 20: | ||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
| ⚫ | |||
| ⚫ | |||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| Line 28: | Line 26: | ||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| ⚫ | |||
| UNII = GO90DFK14U |
|||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| Line 38: | Line 37: | ||
| DrugBank = |
| DrugBank = |
||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = none |
||
| ⚫ | |||
| ⚫ | |||
| chemical_formula = |
| chemical_formula = |
||
| molecular_weight = |
| molecular_weight = |
||
}} |
}} |
||
'''Inolimomab''' is a [[mouse]] [[monoclonal antibody]] developed as an [[immunosuppressive drug]] against [[graft-versus-host disease]]. Its target is the [[CD25|alpha chain]] of the [[interleukin-2 receptor]].<ref name="pmid17085306">{{cite journal | |
'''Inolimomab''' is a [[mouse]] [[monoclonal antibody]] developed as an [[immunosuppressive drug]] against [[graft-versus-host disease]]. Its target is the [[CD25|alpha chain]] of the [[interleukin-2 receptor]].<ref name="pmid17085306">{{cite journal | vauthors = Piñana JL, Valcárcel D, Martino R, Moreno ME, Sureda A, Briones J, Brunet S, Sierra J | display-authors = 6 | title = Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease | journal = Biology of Blood and Marrow Transplantation | volume = 12 | issue = 11 | pages = 1135–1141 | date = November 2006 | pmid = 17085306 | doi = 10.1016/j.bbmt.2006.06.010 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Dartois C, Freyer G, Michallet M, Hénin E, You B, Darlavoix I, Vermot-Desroches C, Tranchand B, Girard P | display-authors = 6 | title = Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease | journal = Clinical Pharmacokinetics | volume = 46 | issue = 5 | pages = 417–432 | year = 2007 | pmid = 17465640 | pmc = 2760126 | doi = 10.2165/00003088-200746050-00004 }}</ref> |
||
==References== |
== References == |
||
{{ |
{{Reflist}} |
||
{{Immunosuppressants}} |
|||
{{immunosuppressants}} |
|||
{{Monoclonals for immune system}} |
{{Monoclonals for immune system}} |
||
{{Interleukin receptor modulators}} |
|||
[[Category:Monoclonal antibodies]] |
|||
{{monoclonal-antibody-stub}} |
{{monoclonal-antibody-stub}} |
||
{{antineoplastic-drug-stub}} |
{{antineoplastic-drug-stub}} |
||
[[it:Inolimomab]] |
|||